New drug combo shows promise for tough ovarian cancer
NCT ID NCT02195973
First seen Feb 14, 2026 · Last updated May 03, 2026 · Updated 13 times
Summary
This early-stage trial tested whether adding a new drug called LDE225 to the standard chemotherapy paclitaxel is safe for women with ovarian cancer that no longer responds to platinum-based treatments. Fifteen women participated. The main goal was to check for side effects and find the best dose of LDE225 to use with paclitaxel.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.